Bausch + Lomb (BLCO) Expected to Announce Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is anticipated to announce its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $1.26 billion for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Bausch + Lomb Price Performance

Shares of NYSE BLCO opened at $16.44 on Tuesday. The stock’s 50-day moving average is $17.59 and its two-hundred day moving average is $18.16. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The company has a market cap of $5.79 billion, a price-to-earnings ratio of -15.65, a price-to-earnings-growth ratio of 2.13 and a beta of 0.46.

Analyst Ratings Changes

Several equities research analysts have weighed in on BLCO shares. Wells Fargo & Company cut their price target on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Thursday, January 16th. Bank of America reaffirmed an “underperform” rating and set a $18.00 price objective on shares of Bausch + Lomb in a research report on Thursday, December 12th. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective for the company. in a research report on Monday, December 2nd. Citigroup cut Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Bausch + Lomb in a research report on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.